HIV Prevention Clinical Trial
Official title:
PrEP-3D RCT: A Randomized Controlled Trial Evaluating An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among Persons Assigned Male at Birth Who Have Sex With Persons Assigned Male at Birth
The PrEP 3D randomized controlled trial (RCT) will study the effectiveness of the PrEP-3D app compared to standard of care for starting pre-exposure prophylaxis (PrEP), continuing PrEP, and adherence to PrEP.
The investigators will be testing a pharmacist-led model of PrEP delivery combined with mobile app-based PrEP support developed by the investigator's team to improve PrEP initiation and persistence. Alto Pharmacy is a full-service online pharmacy already using mobile and web apps to communicate with patients, providers, laboratories, and insurers to provide timely medication delivery. Alto can provide PrEP prescriptions, order laboratory tests, and perform clinical referrals through a collaborative practice agreement (CPA) with SFDPH that allows transfer of these responsibilities. The investigators have integrated online tools with Alto Pharmacy's technology platform to create PrEP-3D: Digital Diary and Delivery, combining a tailored online support tool with the personalized service of a community pharmacy and the convenience of medication delivery. By removing the requirement for initiation and quarterly visits with a primary care physician for PrEP, the PrEP-3D model will expand access to PrEP visits (including for persons who choose not to go to their primary care provider for PrEP) and reduce burden on the health care system. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03411577 -
Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program
|
N/A | |
| Active, not recruiting |
NCT03112369 -
Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use
|
N/A | |
| Not yet recruiting |
NCT03642314 -
HIV Self-testing in Implementation PrEP Study
|
N/A | |
| Completed |
NCT01810315 -
Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity
|
Phase 1 | |
| Completed |
NCT00984971 -
Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet
|
Phase 1 | |
| Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
| Active, not recruiting |
NCT03255915 -
PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)
|
Early Phase 1 | |
| Completed |
NCT05037513 -
Integrated PrEP Interventions for People Who Inject Drugs in Rural Kentucky
|
N/A | |
| Recruiting |
NCT05087680 -
An Acceptance Based PrEP Intervention to Engage Young Black MSM in the South
|
N/A | |
| Recruiting |
NCT05804461 -
Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico
|
N/A | |
| Completed |
NCT03148171 -
Project WERK (Wellness Encouragement Respect Kinship)
|
N/A | |
| Completed |
NCT04791007 -
OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults
|
Early Phase 1 | |
| Recruiting |
NCT05412433 -
Clinic-based HIV Identification and Prevention Project Using Electronic Resources
|
N/A | |
| Active, not recruiting |
NCT03977181 -
The Community PrEP Study to Assess the Acceptance of PrEP Delivered Through CBCT Platforms
|
N/A | |
| Recruiting |
NCT05165745 -
Stick2PrEP Cisgender Women and Trans Individuals
|
N/A | |
| Completed |
NCT03719053 -
Single Dose Truvada Study
|
Phase 1 | |
| Recruiting |
NCT03856580 -
Long-acting Biomedical HIV Prevention in Transgender Women
|
N/A | |
| Completed |
NCT02750540 -
Optimization of a Tenofovir Enema for HIV Prevention
|
Phase 1 | |
| Completed |
NCT01386294 -
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
|
Phase 3 | |
| Completed |
NCT00993811 -
The Shang Ring: A Novel Male Circumcision Device for HIV Prevention
|
Phase 1 |